Main Research Findings
1) Administration of IPAM was shown to elicit anti-aging benefits in mitochondria, while improving rotifer lifespan and reproductive capabilities. .

Selected Data
1) The study completed by the research team of Poeggeler et al investigated the biological effects of indolepropionamide (IPAM), a naturally occurring indole compound structurally related to melatonin and derived from the previously studied indole-3-propionic acid (IPA). The investigators were particularly interested in determining whether IPAM could protect mitochondrial function, preserve the mitochondrial membrane potential, reduce oxidative damage, and influence lifespan in an aging model organism. The study was based on the premise that mitochondria are a major source of cellular reactive oxygen species (ROS) and that age-related mitochondrial dysfunction can contribute to declining energy production and oxidative damage. Rather than focusing exclusively on conventional antioxidant activity, the investigators examined whether IPAM could directly stabilize mitochondrial energy metabolism by influencing electron transport and reducing electron leakage. The experimental strategy therefore incorporated several complementary approaches, including chemical detection of IPAM in brain tissue, assessment of its bioavailability, mitochondrial membrane-potential measurements, analysis of mitochondrial respiratory-complex activity, antioxidant and pro-oxidant assays, protection against mitochondrial toxins, and lifespan experiments in rotifers. The authors also compared IPAM with melatonin and IPA to determine whether its effects were superior to those of structurally related indoles [1].
The first methodological component involved the synthesis and detection of IPAM. The researchers synthesized IPAM from indole-3-propionic acid by first converting the acid to its ethyl ester and subsequently generating a propanoic acid hydrazide intermediate. The hydrazide was then treated with Raney nickel under reflux conditions, followed by chromatographic purification, producing indole-3-propionamide with a reported 96% yield. This synthetic material was subsequently used as a reference standard for biochemical experiments. To investigate whether IPAM actually occurred naturally in biological tissue, the investigators analyzed rat brain samples using high-performance liquid chromatography (HPLC) with fluorometric detection. Brain tissue was homogenized in perchloric acid containing EDTA and sodium metabisulfite, and the resulting supernatants were analyzed using a mobile phase containing methanol, phosphate, citric acid, octanesulfonic acid, and EDTA. Because endogenous IPAM concentrations were initially very low and difficult to quantify reliably, the investigators administered the precursor amino acid L-tryptophan to young male Sprague-Dawley rats. One hour after administration of 300 mg/kg L-tryptophan, brain tissue was analyzed for IPAM, melatonin, and IPA. Synthetic standards were also added to parallel tissue samples to confirm that the endogenous compounds had the same chromatographic retention characteristics as the corresponding standards [1].
A second component of the study evaluated the ability of IPAM to enter the brain and remain available over time. One-month-old male Sprague-Dawley rats received intraperitoneal administration of synthetic IPAM, melatonin, or IPA at a dose of 0.5 mg/kg. Brain samples were collected at 2, 4, and 8 hours after administration, and the concentrations of the respective indoles were measured. This experiment was designed to compare the central bioavailability of IPAM with that of the structurally related compounds. The investigators then prepared mitochondria from the brains of young and aged rats and mice. Male Sprague-Dawley rats aged one and 20 months were used for mitochondrial membrane-potential experiments, while male Swiss Webster mice aged three and 18 months were used for measurements of mitochondrial respiratory-complex activity. Mitochondrial membrane potential was assessed through rhodamine 123 fluorescence quenching following respiration-driven uptake of the dye. Mitochondria were incubated with malate and glutamate to support respiration, and fluorescence was monitored in real time. The resulting potential was calculated using a Nernst-Guggenheim relationship. The investigators tested control mitochondria as well as mitochondria exposed to 10 nM IPAM, melatonin, or IPA to determine whether these compounds could counteract the age-associated decline in mitochondrial energetic capacity.
The researchers also evaluated whether IPAM could protect mitochondria from experimentally induced damage. Three mitochondrial toxins were selected to interfere with mitochondrial function through different mechanisms: doxorubicin, antimycin A, and FCCP. Doxorubicin and antimycin A interfere with mitochondrial electron transport, whereas FCCP acts as a protonophore that dissipates the mitochondrial proton gradient. These compounds were used at 500 nM to induce reductions in mitochondrial membrane potential. The effects of IPAM at 10 nM were then assessed in both young and old mitochondrial preparations to determine whether the compound could prevent or reverse toxin-induced mitochondrial dysfunction. To investigate direct effects on the respiratory chain, the authors prepared intact mitochondria and sub-mitochondrial particles and measured the activities of mitochondrial oxidative complexes. Complex I and complex IV activity were specifically examined, while complex I activity was independently verified by measuring activity associated with the iron-sulfur cluster N2 using an NBT reduction assay. In this assay, mitochondrial particles were incubated with nitroblue tetrazolium in the presence of superoxide dismutase, and formation of reduced diformazan was quantified spectrophotometrically. Control experiments using complex I inhibitors were included to establish the specificity of the reduction reaction [1].
The study additionally examined the antioxidant and potential pro-oxidant properties of IPAM. Test compounds were incubated in a hydroxyl-radical-generating system containing hydrogen peroxide, ferric chloride, and EDTA. Hydroxyl-radical production was quantified through HPLC-electrochemical detection of salicylate oxidation products, specifically 2,3- and 2,5-dihydroxybenzoic acids. Six independent experiments were performed for these measurements. The ability of IPAM to protect biological macromolecules from oxidative injury was evaluated using rat forebrain homogenates exposed to hydrogen peroxide, ferrous sulfate, and ADP to generate hydroxyl radicals. Oxidative DNA damage was quantified by measuring 8-hydroxydeoxyguanosine, and concentration-response experiments were conducted over a range of indole concentrations to calculate IC50 values. Finally, the investigators tested IPAM in the bdelloid rotifer Philodina acuticornis odiosa. Rotifers were maintained individually in isolation cultures using established methods and were treated with IPAM at concentrations of 10, 20, or 30 μM. Lifespan, organism size, offspring production, and reproductive duration were assessed and compared with vehicle-treated controls. The animal experiments involving rats and mice were conducted under approved institutional protocols, while the rotifer experiments used individually housed organisms of defined and uniform age [1].

Discussion
1) The results of the experiment conducted by Poeggeler et al provided evidence that IPAM occurs naturally in rat brain tissue and possesses substantially greater brain bioavailability than the related compounds melatonin and IPA. Initial HPLC measurements detected endogenous IPAM at very low concentrations, estimated to be below 100 pg indole/mg protein, making accurate baseline quantification difficult. To increase the sensitivity of detection, the researchers administered 300 mg/kg L-tryptophan to one-month-old male Sprague-Dawley rats. One hour later, reproducible increases in brain IPAM, melatonin, and IPA were detected. The measured concentrations were approximately 34,669 pg indole/mg protein for IPAM, 713,632 pg indole/mg protein for melatonin, and 281,614 pg indole/mg protein for IPA. Importantly, endogenous IPAM produced an HPLC peak with the same retention time as synthetic IPAM, supporting the conclusion that the compound was naturally present in the brain rather than being an artifact of synthesis. The authors therefore identified IPAM as an endogenous indole that could be increased following administration of its aromatic amino-acid precursor, L-tryptophan [1].
The bioavailability experiment revealed a particularly strong difference between IPAM and the related indoles. Intraperitoneal administration of 0.5 mg/kg melatonin or 0.5 mg/kg IPA failed to substantially increase their already barely detectable baseline concentrations in rat brain. In contrast, the same dose of IPAM produced high brain concentrations that remained detectable for several hours. IPAM concentrations reached approximately 691 ± 23 pg indole/mg protein at two hours, 562 ± 13 pg/mg protein at four hours, and 361 ± 12 pg/mg protein at eight hours after administration. These findings suggested that IPAM could efficiently cross the blood-brain barrier and remain in brain tissue for a relatively prolonged period. The authors attributed this difference, at least in part, to the physicochemical properties of IPAM. Unlike IPA, which possesses an ionizable carboxyl group and is relatively polar, IPAM has an amphiphilic and more lipophilic structure that facilitates membrane penetration. The results therefore supported one of the central motivations for developing IPAM from IPA: improving biological availability while maintaining the beneficial properties associated with indole compounds.
The mitochondrial experiments demonstrated a pronounced age-associated decline in mitochondrial membrane potential and energetic capacity, but this decline was substantially attenuated by IPAM. Brain mitochondria from young and old Sprague-Dawley rats displayed clear differences in membrane potential, with older animals exhibiting a marked reduction in proton-motive force. Addition of melatonin, IPA, or IPAM at 10 nM improved mitochondrial membrane potential in both young and old preparations. However, IPAM produced the strongest effect, with all three compounds differing significantly from untreated controls, while IPAM produced significantly greater effects than either melatonin or IPA. The significance levels indicated that the compounds improved mitochondrial membrane potential at very low concentrations, while IPAM demonstrated particularly strong activity. These findings supported the hypothesis that IPAM could counteract one of the characteristic features of mitochondrial aging: deterioration of the proton gradient required to drive ATP synthesis [1].
IPAM also demonstrated substantial protective activity against experimentally induced mitochondrial injury. Doxorubicin, antimycin A, and FCCP each produced significant reductions in mitochondrial membrane potential in both young and old rat brain mitochondria. When IPAM was added at 10 nM, however, the loss of membrane potential caused by each toxin was markedly reduced. The protective effect was particularly striking for doxorubicin and antimycin A, where IPAM essentially restored mitochondrial membrane potential to levels comparable to untreated controls. FCCP-induced disruption was also significantly antagonized by IPAM, demonstrating that IPAM was not simply associated with higher mitochondrial membrane potential under normal conditions but could also protect mitochondrial energetic function during severe pharmacological stress. These results were important because the three toxins interfere with mitochondrial function through distinct mechanisms, suggesting that IPAM may act at a relatively fundamental level of mitochondrial energy metabolism rather than merely blocking one specific toxic pathway.
Measurements of respiratory-chain activity provided additional evidence for a direct mitochondrial effect. IPAM increased the activity of complex I and complex IV in brain mitochondria, whereas melatonin produced smaller effects. IPAM was shown to significantly increase both complexes compared with untreated controls in young and old mouse mitochondrial preparations. Complex I activity was independently confirmed using the NBT reduction assay targeting the iron-sulfur cluster N2. This second method reproduced the finding that IPAM increased complex I activity. In contrast, no significant change was detected in complex II–III activity. The investigators also reported displacement of known ligands from mitochondrial binding sites, supporting the possibility of direct interaction between IPAM and mitochondrial components. Taken together, these findings suggested that IPAM could influence oxidative phosphorylation directly, particularly through complex I and complex IV. Because complex I is a major site associated with mitochondrial electron leakage and ROS generation, enhancement of its activity was interpreted as potentially reducing inefficient electron transfer and improving the coupling of electron transport to proton-gradient formation [1].

Figure 1: Changes in the activity levels of complexes I and IV, as well as the N2 cluster.
The antioxidant experiments demonstrated that IPAM was highly effective at suppressing hydroxyl-radical formation without exhibiting the pro-oxidant activity observed with several related indoles. IPAM was the most potent compound tested for reducing hydroxyl-radical production and, like IPA, did not produce detectable pro-oxidant reactive intermediates under the experimental conditions. In contrast, serotonin, 6-hydroxymelatonin, and 5-methoxyindoleacetic acid increased hydroxyl-radical formation, demonstrating pro-oxidant behavior. IPAM was also highly effective at preventing oxidative DNA damage in rat forebrain homogenates. The IC50 for IPAM was 0.18 ± 0.03 mM, compared with 1.46 ± 0.16 mM for melatonin and 7.46 ± 0.80 mM for IPA. Thus, under the conditions of this assay, IPAM required substantially lower concentrations than either melatonin or IPA to reduce hydroxyl-radical-mediated DNA damage by 50%. The investigators interpreted these results as evidence that IPAM combined antioxidant activity with the absence of the pro-oxidant behavior seen with certain structurally related compounds [1].
The most dramatic results were obtained in the rotifer lifespan experiments. Treatment with IPAM at 10, 20, and 30 μM produced dose-dependent and statistically significant extensions of lifespan. Mean lifespan increased from 24.6 ± 1.8 days in controls to 58.5 ± 3.3 days with 10 μM IPAM, 81.1 ± 3.7 days with 20 μM, and 90.5 ± 3.8 days with 30 μM. At the highest concentration, lifespan therefore increased by more than threefold compared with controls. The authors described this as an unusually large lifespan extension for this experimental model. IPAM treatment was also associated with increased body size. After 15 days of treatment with 30 μM IPAM, average rotifer length increased from approximately 390 ± 5 μm in controls to 575 ± 6 μm in treated animals. Thus, the longevity effect was accompanied by a substantial increase in organism size rather than an obvious deterioration in growth.
IPAM also improved reproductive outcomes in the rotifers. Control animals produced an average of approximately 16 ± 1 offspring over their lifetime, whereas animals treated daily with 30 μM IPAM produced approximately 55 ± 1 offspring, representing roughly a threefold increase. Lower concentrations of 10 and 20 μM also increased offspring production, with averages of approximately 52 ± 2 and 53 ± 2 offspring, respectively. The duration of the reproductive period was similarly extended. Control rotifers remained fertile for approximately 5 ± 1 days, compared with approximately 18 ± 1 days for animals receiving 30 μM IPAM. The lower concentrations also increased reproductive duration, to approximately 13 ± 1 and 16 ± 1 days for 10 and 20 μM IPAM, respectively. The effects on lifespan, size, fertility, and reproductive duration were statistically significant [1].
Overall, the results supported the authors’ conclusion that IPAM is a naturally occurring indole with potentially important effects on mitochondrial metabolism and aging-related processes. The compound demonstrated high brain bioavailability, preserved mitochondrial membrane potential in aged preparations, protected against several mitochondrial toxins, increased complex I and IV activity, and strongly reduced hydroxyl-radical-mediated oxidative damage without demonstrating the pro-oxidant behavior observed with several related indoles. In the rotifer model, IPAM produced exceptionally large lifespan extensions while simultaneously increasing body size, offspring production, and reproductive lifespan. The authors proposed that IPAM may function as a mitochondrial metabolism modifier, potentially acting as an electron and proton carrier that improves mitochondrial electron flow, maintains the proton gradient, supports ATP production, and reduces electron leakage and ROS generation. They emphasized, however, that the mechanisms responsible for the dramatic effects on rotifer growth and fertility remained unresolved. The study ultimately presented IPAM as a potentially important endogenous mitochondrial-protective and anti-aging molecule, while suggesting that its possible relevance to age-related neurodegenerative diseases and mitochondrial disorders would require further investigation [1].

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

Citations

[1] Poeggeler B, Sambamurti K, Siedlak SL, Perry G, Smith MA, Pappolla MA. A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan. PLoS One. 2010;5(4):e10206. Published 2010 Apr 21. doi:10.1371/journal.pone.0010206

Indolepropionamide (IPAM) is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.